2 research outputs found
Role of copeptin in diagnosis and outcome prediction in patients with heart failure: a systematic review and meta-analysis
Heart failure (HF) is a heterogeneous condition characterized by increased morbidity and mortality. This systematic review and meta-analysis of 19 studies was conducted to evaluate the role of copeptin in diagnosis and outcome prediction in HF patients. A systematic literature search for clinical trials reporting copeptin levels in HF patients was performed using EMBASE, PubMed, Cochrane Register of Controlled Trials, and Google Scholar. Articles from databases published by 2 January 2022, that met the selection criteria were retrieved and reviewed. The random effects model was used for analyses. Pooled analysis found higher mean copeptin levels in HF vs. non-HF populations (43.6βΒ±β46.4 vs. 21.4βΒ±β21.4; MD= 20.48; 95% CI: 9.22 to 31.74; pβpβ=β0.001). Copeptin level was higher in patients with mortality/acute HF-related hospitalization vs. stable patients (31.3βΒ±β23.7 vs. 20.4βΒ±β12.8; MD= β13.06; 95% CI: β25.28 to β0.84; pβ=β0.04). Higher copeptin concentrations were associated with mortality and observed in all follow-up periods (pβ The present meta-analysis showed that elevated copeptin plasma concentrations observed in HF patients are associated with an increased risk of all-cause mortality, thus copeptin may serve as predictor of outcome in HF.</p